What is the Association of Depression with Clinical Response to Therapy in Patients with Psoriatic Arthritis Treated with Biologic Disease-modifying Antirheumatic Drugs?

Overview

Journal Clin Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2023 Nov 13

PMID 37957488

Authors

Ana Martins

Daniela Oliveira

Rafaela Nicolau

Teresa Martins Rocha

Alexandra Bernardo

Lucia Costa

Sofia Pimenta

Miguel Bernardes

Affiliations

Soon will be listed here.

Abstract

Introduction: Psoriatic arthritis (PsA) is a chronic, progressive inflammatory joint disease that is associated with higher prevalence of depression. There is limited literature about the impact of depression, particularly regarding the response to therapy.

Methods: A retrospective cohort study with PsA patients that started their first biologic disease-modifying antirheumatic drugs (bDMARD) was conducted. In the majority of cases, a cutoff score of ≥ 8 in Hospital Anxiety and Depression Scale (HADS) was used to define cases of depression. In cases where patients did not complete the questionnaire, a previous diagnosis made by a psychiatrist was used to establish the presence of depression. Response to therapy 12 months after the start of bDMARD was evaluated and the switch rate to another bDMARD due to inefficacy was assessed at month 12.

Results: A total of 129 patients (66 females, 51.2%; mean age of 47.7 ± 11.0 years and mean disease duration of 10.0 ± 7.7 years) with PsA were included. Thirty-two (24.8%) patients had depression. Patients with depression and peripheral involvement had a significantly lower ACR20/50/70 responses (p = 0.001, p = 0.002, and p = 0.001 respectively) after 12 months of therapy and a significantly worse EULAR response (p = 0.002). Furthermore, patients with depression and axial involvement had a significantly worse response based on ASDAS response criteria (p = 0.031). Switch due to ineffectiveness in the first 12 months was significantly higher in patients with depression (p = 0.002).

Conclusion: Depression in PsA is a frequent yet often understudied comorbidity. The causal relationship between depression and PsA is difficult to decrypt and further research is needed. Recognition of depressive symptoms is crucial and a multidisciplinary approach should be provided to individuals with this comorbidity. Key Points • Depression in PsA is a frequent yet often understudied comorbidity. In our study, the prevalence of depression was 24.8%. • Depression in PsA seems to be associated to lower response to therapy and higher discontinuation rates of bDMARD. • Recognition of depressive symptoms is crucial and a multidisciplinary approach should be provided to individuals with this comorbidity.

References

Alinaghi F, Calov M, Kristensen L, Gladman D, Coates L, Jullien D . Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2018; 80(1):251-265.e19. DOI: 10.1016/j.jaad.2018.06.027. View

Scotti L, Franchi M, Marchesoni A, Corrao G . Prevalence and incidence of psoriatic arthritis: A systematic review and meta-analysis. Semin Arthritis Rheum. 2018; 48(1):28-34. DOI: 10.1016/j.semarthrit.2018.01.003. View

Bandinelli F, Prignano F, Bonciani D, Pallanti S, Lotti T, Salaffi F . Clinical and demographic factors influence on anxiety and depression in early psoriatic arthritis (ePsA). Clin Exp Rheumatol. 2013; 31(2):318-9. View

McDonough E, Ayearst R, Eder L, Chandran V, Rosen C, Thavaneswaran A . Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol. 2014; 41(5):887-96. DOI: 10.3899/jrheum.130797. View

Kim H, Kim S, Cho Y . Combined Effects of Depression and Chronic Disease on the Risk of Mortality: The Korean Longitudinal Study of Aging (2006-2016). J Korean Med Sci. 2021; 36(16):e99. PMC: 8076848. DOI: 10.3346/jkms.2021.36.e99. View

Duvetorp A, Ostergaard M, Skov L, Seifert O, Tveit K, Danielsen K . Quality of life and contact with healthcare systems among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP). Arch Dermatol Res. 2019; 311(5):351-360. PMC: 6546664. DOI: 10.1007/s00403-019-01906-z. View

Hermesdorf M, Berger K, Baune B, Wellmann J, Ruscheweyh R, Wersching H . Pain Sensitivity in Patients With Major Depression: Differential Effect of Pain Sensitivity Measures, Somatic Cofactors, and Disease Characteristics. J Pain. 2016; 17(5):606-16. DOI: 10.1016/j.jpain.2016.01.474. View

Thompson T, Correll C, Gallop K, Vancampfort D, Stubbs B . Is Pain Perception Altered in People With Depression? A Systematic Review and Meta-Analysis of Experimental Pain Research. J Pain. 2016; 17(12):1257-1272. DOI: 10.1016/j.jpain.2016.08.007. View

Zhao S, Holmes M, Alam U . Disentangling the relationship between depression and chronic widespread pain: A Mendelian randomisation study. Semin Arthritis Rheum. 2023; 60:152188. DOI: 10.1016/j.semarthrit.2023.152188. View

10.

Michelsen B, Kristianslund E, Sexton J, Hammer H, Fagerli K, Lie E . Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study. Ann Rheum Dis. 2017; 76(11):1906-1910. DOI: 10.1136/annrheumdis-2017-211284. View

11.

Katon W, Ciechanowski P . Impact of major depression on chronic medical illness. J Psychosom Res. 2002; 53(4):859-63. DOI: 10.1016/s0022-3999(02)00313-6. View

12.

DiMatteo M, Lepper H, Croghan T . Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000; 160(14):2101-7. DOI: 10.1001/archinte.160.14.2101. View

13.

Lewinson R, Vallerand I, Lowerison M, Parsons L, Frolkis A, Kaplan G . Depression Is Associated with an Increased Risk of Psoriatic Arthritis among Patients with Psoriasis: A Population-Based Study. J Invest Dermatol. 2017; 137(4):828-835. DOI: 10.1016/j.jid.2016.11.032. View

14.

Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H . Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006; 54(8):2665-73. DOI: 10.1002/art.21972. View

15.

Herrmann C . International experiences with the Hospital Anxiety and Depression Scale--a review of validation data and clinical results. J Psychosom Res. 1997; 42(1):17-41. DOI: 10.1016/s0022-3999(96)00216-4. View

16.

Brennan C, Worrall-Davies A, McMillan D, Gilbody S, House A . The Hospital Anxiety and Depression Scale: a diagnostic meta-analysis of case-finding ability. J Psychosom Res. 2010; 69(4):371-8. DOI: 10.1016/j.jpsychores.2010.04.006. View

17.

Wells G, Becker J, Teng J, Dougados M, Schiff M, Smolen J . Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on.... Ann Rheum Dis. 2008; 68(6):954-60. PMC: 2674547. DOI: 10.1136/ard.2007.084459. View

18.

Aletaha D, Nell V, Stamm T, Uffmann M, Pflugbeil S, Machold K . Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005; 7(4):R796-806. PMC: 1175030. DOI: 10.1186/ar1740. View

19.

Smolen J, Breedveld F, Schiff M, Kalden J, Emery P, Eberl G . A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003; 42(2):244-57. DOI: 10.1093/rheumatology/keg072. View

20.

Fries J, Spitz P, Kraines R, HOLMAN H . Measurement of patient outcome in arthritis. Arthritis Rheum. 1980; 23(2):137-45. DOI: 10.1002/art.1780230202. View